How Pfizer Is Rethinking What’s Possible in Cancer Care

Photograph of lab scientists, one using a microscope, working in a bright laboratory.

For people living with cancer and those who love them, every moment matters. Cancer remains one of the greatest healthcare challenges of our lifetime, and Pfizer is working with urgency to transform scientific advances into potential life-changing medicines.

In a sponsored interview, Jeff Legos, Pfizer’s Chief Oncology Officer, sat down with Jessica Sibley, CEO of TIME, to discuss why this mission is personal for him, the responsibility he feels as Pfizer works toward its ambition of delivering eight cancer breakthroughs by 2030, and the role AI will play in the fight.

“It gives us the opportunity to take years, if not decades, of leadership, legacy, experience, expertise, and data across all cancers to be able to truly learn and ultimately predict what could be the next best molecule, scientific target, or possible medicine,” Legos says.

AI is already helping Pfizer researchers identify promising molecules and targets, while conducting simulations to help determine which clinical-trial approaches have the highest probability of success. Pfizer is also embedding AI into clinical-trial design and execution, with some processes that once took years happening roughly 50% faster, all for the benefit of patients.

“We have an enormous responsibility that we carry on our shoulders every single day. Patients are waiting and families are counting on us.”

Watch the full interview.

Pfizer’s Chief Oncology Officer Sits Down with TIME

Pfizer Learns to Speak AI with Fluency Program

Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI).

Pfizer Learns to Speak AI with Fluency Program

Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI).

After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission

In 2013, Josh Raub’s life was going according to plan. At 29 years old, he was working at his dream job as a professor and pharmacy specialist at an academic medical center in Detroit. He and his wife had just bought their first home and were talking about starting a family. “It was just this perfect future that we were planning for ourselves,” he says. Then he got sick.

After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission

September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More

As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.

September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More

As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.

Bourla at Concordia: The Business of Better Health

At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."

Bourla at Concordia: The Business of Better Health

At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."

How AI Is Helping Match Patients to Clinical Trials Faster

Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.